Drug Trial Radar · NCT07509086
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Jul 15, 2028
Study completion Jul 15, 2029
Sponsor
- Lead sponsor
- The First Hospital of Jilin UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.
Conditions
- Relapsed/Refractory Multiple Myeloma
- Plasma Cell Leukemia (PCL)
Interventions
IL-15-armored CAR-T cellsBiological
BCMA-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; CD19/BCMA dual-targeted: 1.0/1.5/2.0 × 10\^6 CAR-T cells; GPRC5D-targeted: 1.0/2.0/3.0 × 10\^6 CAR-T cells.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR)Time frame: From infusion to 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.